Cytokinetics Inc (NAS:CYTK)
$ 48.98 -10.25 (-17.31%) Market Cap: 5.14 Bil Enterprise Value: 6.35 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Cytokinetics Inc Call to Discuss the Full Results from REDWOOD-HCM Transcript

Sep 13, 2021 / 12:30PM GMT
Release Date Price: $31.48 (+6.64%)
Operator

Good afternoon, and welcome, ladies and gentlemen, to the Cytokinetics call announcing the full results of REDWOOD-HCM. At this time, I would like to inform you that this call is being recorded. (Operator Instructions)

I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser
Cytokinetics, Incorporated - SVP of Corporate Communications & IR

Welcome, everyone, and thanks for joining us this morning on the call today, focused on the full results of REDWOOD-HCM, the Phase II clinical trial of aficamten, our next-in-class cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathy, or HCM. Robert Blum, our President and Chief Executive Officer, will lead us off with an overview of yesterday's announcement. Then Fady Malik, our Executive Vice President of R&D, will discuss the next-in-class properties of aficamten and how it was designed to optimize clinical utility as could be assessed in a trial like REDWOOD-HCM.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot